Patients Cut Off From Cheaper Obesity Drugs as FDA Halts Sales of Copycats
U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or suspend treatment for patients.
Source link
atOptions = {
'key' : '935d6ab39f70f5664bb173656c8b20f0',
'format' : 'iframe',
'height' : 250,
'width' : 300,
'params' : {}
};
